One of the first promising results was presented in 2019 by Danylesko et al. [21] An AML patient with t(8;21) (q22;q22.1) after relapse after alloHSCT was given the second-generation CAR-T cells with the cluster of differentiation 28 (CD28) as a co-stimulatory domain in a dose of 1 × 106 CAR T cells/kg. This evidence concerns the gene CD28 and acute myeloid leukemia.